Table 2: Additional interventions required during follow-up.
SLT
ALT
2
0
5
10
17
7
14
15
10
1
1
0
49
33
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.